18 Sep 2025 | 3 Mins Read
Novo Nordisk shares jump 5% on 'significant' weight reduction news
Flipitmoney
Novo Nordisk announced "significant" weight reduction in its once-daily obesity pill study, with patients achieving an average 16.6% weight loss after 64 weeks. The trial, Oasis 4, demonstrated tolerability in line with the popular Wegovy injection. Shares jumped 5.4% as the company seeks a competing oral treatment to its existing injection.